Dalcetrapib vs Obicetrapib/ezetimibe (Evlarco)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline

Dalcetrapib

Developed by DalCor Pharmaceuticals under a licence from Roche

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT01516541 · Phase 3 · completed

The study was randomized and double-blind, compared dalcetrapib with placebo, and enrolled 2,220 participants. Its primary endpoint was a hard clinical composite cardiovascular outcome, but the comparison cannot be judged because trial results have not been posted.

Next expected readout: August 2027 · NCT05918861 (registry estimate)

Reported efficacy

Incidence of Cardiovascular Mortality and Morbidity (From date of randomization to first event up to 48 months): Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). (missed)

Result source: NCT00658515

Obicetrapib/ezetimibe (Evlarco)

Marketed by A. Menarini under a licence from NewAmsterdam Pharma

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT06005597 · Phase 3 · completed

The study was randomized, quadruple-blind, and placebo- and active-controlled, with 407 participants distributed across four treatment groups. All four prespecified LDL-C comparisons significantly favored the obicetrapib-containing treatment, but LDL-C is a laboratory surrogate rather than a hard clinical endpoint, so the evidence is rated moderate.

Reported efficacy

Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C (84 Days); Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C (84 Days); Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C (84 Days): Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) (met)

Result source: NCT06005597

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDalcetrapibObicetrapib/​ezetimibe (Evlarco)
LDL-C, % change—Not posted · NCT01516541—Not reported
Non-HDL-C, % change—Not posted · NCT01516541—Not reported
ApoB, % change—Not posted · NCT01516541—Not reported
Lp(a), % change—Not posted · NCT01516541—Not reported
3-point MACE (% with event)—Not posted · NCT01516541—Not reported

LDL-C, % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

Non-HDL-C, % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

ApoB, % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

Lp(a), % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib/​ezetimibe (Evlarco)
—Not reported

3-point MACE (% with event)

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib/​ezetimibe (Evlarco)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Obicetrapib/ezetimibe (Evlarco)
Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564) NCT06005597 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dalcetrapib: 3 of 4 rows · Obicetrapib/ezetimibe (Evlarco): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDalcetrapib
Dropout rate
2.1%a
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
17.2%
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
10.8%900mg
NCT00697203 · Phase 2 · registry result, not featured evidence
8.8%600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
11.8%300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
—
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
—900mg
NCT00697203 · Phase 2 · registry result, not featured evidence
—600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
—300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
Serious AEs
12.9%a
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
31.3%
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
4.1%900mg
NCT00697203 · Phase 2 · registry result, not featured evidence
2.9%600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
2.6%300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
chest pain 10.1% (placebo 7.8%)
diarrhea 8.6% (placebo 5.8%)
hypertension 8% (placebo 4.1%)
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dalcetrapib

PAV 0.6% (n=474) vs 0.5% (n=462) placebo @ 104wk
percent change · % of baseline
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
CIMT Change Rate MM Per 0.003 vs 0.003 placebo per year @ 104wk
absolute change · per year
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Minimal Lumen Diameter Change -0.1 vs 0 placebo mm @ 104wk
absolute change · mm
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Percent Diameter Stenosis 9.2% (n=474) vs 4.3% (n=462) placebo @ 104wk
absolute change · percentage points
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Wall Thickness 4.245% (n=64) vs 6.679% (n=66) placebo @ 104wk
percent change · % of baseline
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
Plaque Target to Background -0.188 vs -0.26 placebo ratio @ 26wk
ratio to baseline · ratio
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
HDL-C Change mg/dL 36.45 vs 2.31 placebo mg/dL @ 12wk900mg
absolute change · mg/dL
NCT00697203 · Phase 2 · registry result, not featured evidence
show 2 more results
31.42 vs 2.31 placebo mg/dL @ 12wk600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
17.18 vs 2.31 placebo mg/dL @ 12wk300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
HDL-C 13.92% (n=72) vs 0.73% (n=73) placebo @ 12wk900mg
percent change · % of baseline
NCT00697203 · Phase 2 · registry result, not featured evidence
show 2 more results
11.9% (n=67) vs 0.73% (n=73) placebo @ 12wk600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
6.58% (n=75) vs 0.73% (n=73) placebo @ 12wk300mg
NCT00697203 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalcetrapib's landscape · Obicetrapib/ezetimibe (Evlarco)'s landscape